The closing price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was $0.17 for the day, down -7.22% from the previous closing price of $0.19. In other words, the price has decreased by -$0.0135 from its previous closing price. On the day, 5494850 shares were traded.
Ratios:
Our analysis of TNXP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.78 and its Current Ratio is at 2.53. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 14.70M and an Enterprise Value of -433.59k. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.89 while its Price-to-Book (P/B) ratio in mrq is 0.10. Its current Enterprise Value per Revenue stands at -0.11 whereas that against EBITDA is 0.00.
Stock Price History:
Over the past 52 weeks, TNXP has reached a high of $3.75, while it has fallen to a 52-week low of $0.17. The 50-Day Moving Average of the stock is 0.3264, while the 200-Day Moving Average is calculated to be 0.6881.
Shares Statistics:
TNXP traded an average of 1.95M shares per day over the past three months and 5.59M shares per day over the past ten days. A total of 84.49M shares are outstanding, with a floating share count of 84.49M. Insiders hold about 0.01% of the company’s shares, while institutions hold 19.87% stake in the company. Shares short for TNXP as of Mar 15, 2024 were 967.03k with a Short Ratio of 0.50, compared to 596.5k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.65% and a Short% of Float of 1.65%.
Earnings Estimates
The firm’s stock currently is rated by 1 analysts. On average, analysts expect EPS of -$1.35 for the current quarter, with a high estimate of -$1.35 and a low estimate of -$1.35, while EPS last year was -$3.25. The consensus estimate for the next quarter is -$1.42, with high estimates of -$1.42 and low estimates of -$1.42.
Analysts are recommending an EPS of between -$0.91 and -$5.83 for the fiscal current year, implying an average EPS of -$3.14. EPS for the following year is -$1.21, with 2 analysts recommending between -$0.52 and -$1.91.
Revenue Estimates
Based on 2 analysts’ estimates, the company’s revenue will be $24.5M in the next fiscal year. The high estimate is $30M and the low estimate is $19M. The average revenue growth estimate for next year is up 46.10% from the average revenue estimate for this year.
